Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo‐controlled randomized clinical trials

20227 citationsJournal Articlebronze Open Access

Authors

Individuals with migraine not experiencing ≥50% MMD response to their first dose of eptinezumab may benefit from a second dose.

Good health and well-being

Published in: Headache The Journal of Head and Face Pain

Volume 62, Issue 5, pp. 558-565

Field-Weighted Citation Impact: 0.90